SK Discovery subsidiary SK Plasma raised a Saudi blood-products supply contract to ₩46.22 billion from ₩18.37 billion. The update adds confirmed 2027 volumes to the 2026 amount. The revised value equals 21.11% of SK Plasma's 2025 consolidated revenue. The buyer must pay in full before shipment. Volumes and prices for 2028 and 2029 are not set and will be agreed in the preceding year's second half.